T
he number of circulating endothelial progenitor cells inversely relates to cardiovascular disease (CVD) (1) (2) (3) ; microalbuminuria is one of the earliest manifestations of diabetic nephropathy and a marker of CVD (4) . A subset of patients with type 1 diabetes is susceptible to diabetic nephropathy, a condition characterized by a higher risk of cardiovascular morbidity and mortality (4, 5) . Type 1 diabetic patients without complications have a lower number of circulating progenitor cells than healthy control subjects (6, 7) . To gain insight into the susceptibility to CVD in type 1 diabetes, we studied circulating vascular progenitor cell number and function in type 1 diabetic patients with and without microalbuminuria.
RESEARCH DESIGN AND METHODS -Type 1 diabetic patients were recruited from Guy's and St Thomas' Hospital (London, U.K.). Patients with microalbuminuria (MA ϩ ) had a positive history of early-morning urine albumin-to-creatinine ratio (ACR) Ն3.5 mg/mmol (in at least two of three consecutive measures), were on antihypertensive therapy, and had evidence of diabetic retinopathy.
The normoalbuminuric (MA Ϫ ) type 1 diabetic patients were defined as patients with Ն20 years' diabetes duration, ACR consistently Ͻ3.5 mg/mmol, and on no antihypertensive therapy.
Exclusion criteria were as follows: history of CVD, nondiabetic renal disease, and renal impairment defined as a serum creatinine Ͼ130 mol/l. The study was approved by the local ethics committee.
Blood pressure, measured in the dominant arm with the patient seated after a 5-min rest using an automated sphygmomanometer (Dinamap-8100T; GE-Medical, Slough, U.K.), was calculated from the mean of three consecutive measurements. Fasting plasma glucose, serum total cholesterol, and creatinine were determined using a Cobas-MiraPlus analyzer (Roche-Diagnostics, Basel, Switzerland). A1C was measured by liquid chromatography (Primus-CLC330; Primus Diagnostic, Kansas City, MO).
Circulating progenitor cells were investigated as described (3) . Leukocytes were studied from peripheral blood after red cell lysis with ammonium chloride buffer. At least 500 CD34 ϩ /CD133 ϩ events were collected for each patient and showed Ͼ1 ϫ 10 6 events in the lymphomonocyte gated area. Intra-assay coefficient of variation was Ͻ8%. Data are presented as events/10 6 lymphomonocytes (Fig. 1) .
The cell colony-forming units-Hill (CFU-Hill) assay was performed as described (2) . For the tube formation assay, early (7-day culture) and late (14-day culture) endothelial progenitor cells were studied in the presence and absence of vascular endothelial growth factor (VEGF)-A (3, 8) . Cells were characterized by immunofluorescence (supplementary Fig. 1 , available in an online appendix at http://care.diabetesjournals.org/cgi/ content/full/dc09-1468/DC1).
Measurements and data analysis (SPSS-15) were performed blinded to group allocation. Not-normally and normally distributed variables were compared by Kruskall-Wallis and Student's t test (two-sided), respectively; when more than two groups were compared, ANOVA (least significance difference post hoc test) was used. P Յ 0.05 was considered statistically significant. ϩ /KDR ϩ cell number was similar between groups ( Fig. 1A and B) .
The Tube formation experiments were conducted in 9 MA ϩ (5 males/4 females) and 7 MA Ϫ (4 males/3 females) type 1 diabetic consecutive patients as above. In experiments with early endothelial progenitor cells, we did not observe differences between groups. In experiments with late endothelial progenitor cells, we observed a VEGF-A-mediated increase in tube surface area only in MA Ϫ patients; MA ϩ patients had a significantly lower tube number than MA Ϫ patients (Fig. 1C and D) .
CONCLUSIONS -We demonstrated a lower number of circulating CD34 ϩ and CD34 
Vascular risk and microalbuminuria in diabetes
patients, suggesting impaired vascular repair processes in MA ϩ (3). Microalbuminuria is a strong predictor for CVD in longstanding type 1 diabetic patients (5), and in our study, microalbuminuria associates with a low number of circulating progenitor cells, a recognized marker of CVD.
ACE inhibitors increase the number and function of vascular progenitor cells (9) ; despite a more prevalent use of these medications in the MA ϩ group, we still observe a significantly lower number of CD34 ϩ , CD34 ϩ /CD133 ϩ , and impaired tube formation in MA ϩ patients. Conversely, the effect of statins on progenitor cells has been controversial (9, 10) , and this may represent a confounder in our study.
The number of CD34 ϩ /KDR ϩ and CD34 ϩ /CD133 ϩ cells is reduced in hypertensive patients (11); normalization of blood pressure with renin-angiotensin system inhibitors is paralleled by normalization of these cells (11) . This suggests that in our type 1 diabetic/MA ϩ population (100% on ACE inhibitors), the observed reduction in CD34 ϩ and CD34 ϩ / CD133 ϩ cells is independent of blood pressure. Further, we found no correlation between systolic or diastolic blood pressure and CD34 ϩ and CD34 ϩ / CD133 ϩ within the MA ϩ or MA Ϫ groups. Our observations are in line with the described inverse relationship between CD34 ϩ cells and progression of nephropathy in type 2 diabetes (12). Indeed, significant renal impairment affects progenitor cell number and function (13); however, both our groups had relatively preserved and comparable renal function, and we did not observe a correlation between progenitor cell number and eGFR.
All our patients had retinopathy; however, its severity was not measured. The observation that microalbuminuric diabetic patients have more severe retinopathy (14) , a condition paralleled by higher circulating progenitor cells (15) , could have underestimated the observed differences.
In conclusion, in a relatively "protected" population of type 1 diabetic patients, with or without microalbuminuria, circulating vascular progenitor cells may be a mean by which individuals respond to the vascular risk linked with diabetes and improve their long-term vascular health, while others, unable to respond to insults, are at higher risk for renal and vascular diseases.
